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ABSTRACT 
Objective: The main objective of this research work was to formulate and evaluate fast dissolving tablet of verapamil hydrochloride for the 
treatment of hypertension. 
Methods: In this study, fast dissolving tablet were prepared by wet granulation method by using croscarmellose sodium and sodium starch glycolate as 
superdisintegrants in the concentration of 2%, 4%, and 6%. Polyvinyl pyrollidone K30 is used as a binder. The designed tablets were subjected to 
various assessment parameters like friability test, hardness test, disintegration test, wetting time, in vitro drug release and drug content.  
Results: All the prepared formulations were subjected to various assessment parameters, and the findings obtain within the prescribed limit. The 
calibration curve of pure drug using various solvents like distilled water, phosphate buffer pH 6.8 was plotted. F1-F9 containing croscarmellose 
sodium and sodium starch glycolate in various concentration demonstrate the minimum disintegration time. Among all these formulations F8 
shows disintegration time upto 19±0.06 seconds due to the high concentration of superdisintegrants. In vitro drug release was tested in phosphate 
buffer pH 6.8 at a time interval of 0, 1, 3,6,9,12,15 min. The F8 shows drug release 98.5±0.567%. Accelerated stability study of optimized 
formulation (F8) up to 2 mo showed there was no change in disintegration time and percentage drug release.  
Conclusion: The results obtained in the research work clearly showed a promising potential of fast dissolving tablets containing a specific ratio of 
crosscarmellose sodium and sodium starch glycolate as superdisintegrants for the effective treatment of hypertension.  
Keywords: Fast dissolving tablet, Verapamil hydrochloride, Superdisintegrants, Bioavailability, Calcium channel blocker 




Oral drug delivery remains the preferred route for administration of 
various drugs. Solid dosage forms are popular because of ease of 
administration, accurate dosage, self-medication, pain evasion and most 
importantly the patient compliance. Tablets and capsules are the most 
popular dosage forms. But one important drawback of such dosage 
forms is dysphagia or difficulty in swallowing. To solve the above-
mentioned problem, pharmaceutical technologists have put in their best 
efforts to develop a fast dissolving drug delivery, i.e. mouth dissolving 
tablet that disintegrates and dissolves rapidly in the saliva, within a few 
seconds without the need of drinking water or chewing. Such 
formulations provide an opportunity for product line extension in the 
many elderly persons will have difficulties in taking conventional oral 
dosage forms (viz., solutions, suspensions, tablets, and capsules) because 
of hand tremors and dysphagia. Other groups that may experience 
problems using conventional oral dosage forms include the mentally ill, 
the developmentally disabled and patients who are uncooperative, on 
reduced liquid-intake plans, or are nauseated. The technologies utilized 
for fabrication of fast dissolving tablet include lyophilization, molding, 
direct compression, cotton candy process, spray drying, sublimation, 
mass extrusion, nanonization, and quick dissolve film formation.  
In case of geriatric and pediatric patients, there is a problem of 
dysphasia i.e. difficulty in swallowing. The oral bioavailability of 
verapamil hydrochloride is 35% due to first pass metabolism; 
therefore the bioavailability of the drug is increased by formulating 
fast-dissolving drug delivery system. Bioavailability is increased due 
to absorption from mouth to pharynx and pharynx to the esophagus. 
Thus, in the present investigation, it was planned to formulate and 
evaluate fast dissolving tablet of verapamil hydrochloride [1-11]. 
MATERIALS AND METHODS 
Materials 
Verapamil hydrochloride procured from Swapnroop drug agency, 
Aurangabad. All the other reagents used were of analytical grade.  
Methods 
Determination of λ max of verapamil hydrochloride 
The UV spectrum of verapamil hydrochloride was obtained by using 
a UV-visible spectrometer (UV 3000). Accurately weigh 10 mg of the 
drug was added to 100 ml of volumetric flask. Volume was made up 
to 100 ml with water (100 μg/ml). This solution was used as a stock 
solution. From the stock solution, 1 ml of aliquots was withdrawn, 
and the volume was made up to 10 ml using water to obtain the 
concentration of 10 μg/ml. The resultant solution was scanned from 
400 to 200 nm, and the spectrum was recorded to obtain the value 
of the maximum wavelength in respective solvents [12]. 
Drug excipients compatibility study 
Infrared spectrum 
The infrared (IR) spectrum of verapamil hydrochloride was 
recorded with potassium bromide (KBr) discover the wave number 
of 4000 to 400 cm-1
A 3
by using fourier transform infrared spectro-
photometer (FTIR) [13]. 
Formulation of fast dissolving tablets 
Weighed a required quantity of all powdered material and mixed 
properly. Then granules were prepared by the addition of binder 
solution in the powdered material until dump mass is get formed. 
These dump mass is screened properly to obtain pellets or granules. 
After drying milling of the dried mass and then mixed with other 
ingredients like lubricant or gliadant. 
Formulation optimization 
2 factorial design was applied to a formulation that shows the 
satisfactory results to see the effect of varying concentration of 
independent variables croscarmellose sodium(X1), sodium starch 
glycolate (X2) on dependent variables like disintegration time and 
cumulative drug release [14]. 
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Table 1: Independent variables 
Independent variables  Levels 
Lower (-1) Middle (0) Upper (-1) 
crosscarmellose sodium  3 6 9 
sodium starch glycolate  3 6 9 
  
Table 2: Composition of fast dissolving tablet of verapamil hydrochloride 
S. No. Excipients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 verapamil hydrochloride 20 20 20 20 20 20 20 20 20 
2 crosscarmellose sodium  3 3 3 6 6 6 9 9 9 
3 sodium starch glycolate 3 6 9 3 6 9 3 6 9 
4 polyvinyl pyrollidone K30 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
5 magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
6 talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
7 mannitol 118.5 115.5 112.5 115.5 112.5 109.5 112.5 109.5 106.5 




Angle of repose (θ) 
Angle of repose is defined as the maximum angle possible between 
the surface of a pile of the powder and horizontal plane. The 
frictional force in loose powder or granules can be measured by the 
angle of repose [1, 15]. 
 
θ = tan-1
Where θ is the angle of repose 
 (h/r) 
h is the height of pile  
r is the radius of the base of the pile 
Bulk density  
A quantity of accurately weighed drug excipient powder blend from 
each formula, previously shaken to break any agglomerates formed 
was introduced into a 25 ml measuring cylinder, and the initial volume 
was noted and bulk density calculated by following formula [15]: 
 
Tapped density 
After the initial volume was observed, the cylinder was allowed to 
fall under its own weight onto a hard surface from the height of 2.5 
cm at 2 Sec intervals. The taping was continued until no further 
change in volume was noted [15]. 
 
Hausner’s ratio:  
Hausner’s ratio is an indirect index of ease of power flow [15].  





Where ρt  is tapped density and ρd
Carr’s compressibility index 
 is bulk density. 
The compressibility index of the granules was determined by the 
Carr’s compressibility index. (%) Carr’s Index can be calculated by 
using the following formula [15]. 
 
Post compressional parameters of all tablet formulations 
Hardness test 
Tablets require a certain amount of strength, or hardness and 
resistance to friability, to withstand mechanical shocks of handling 
during manufacture, packaging, and shipping. The hardness of the 
tablets was determined using digital hardness tester. It is expressed 
in Kg/cm2
Friability test 
. Three tablets were randomly picked from each 
formulation, and the mean and standard deviation values were 
calculated. Average of triplicate is taken [15, 16]. 
It is the phenomenon whereby tablet surfaces are damaged and/or 
show evidence of lamination or breakage when subjected to 
mechanical shock or attrition.  
The friability of tablets was determined by using electro lab, USP EF 2 
friabilator. It is expressed in percentage (%). Ten tablets were initially 
weighed (W initial) and transferred into friabilator. The friabilator was 
operated at 25 RPM for 4 min. The tablets were weighed again (W final
F = 
). 
The percentage friability was then calculated by, 
100x
W




% Friability of tablets less than 1% is considered acceptable. 
Average of triplicate is taken [16, 17].  
Weight variation test 
The 20 tablets were selected randomly from each formulation and 
weighed individually to check for weight variation. The Indian 
pharmacopoeia allows a little variation in the weight of a tablet. 
Average weight was calculated, and the standard deviation was 
computed. Average of 20 readings is taken [15, 16]. 
Uniformity of thickness 
The thickness of individual tablet may be measured with a digital 
vernier calliper, which permits accurate measurements and 
provides information on the variation between tablets. Averages of 
triplicate readings were taken [15]. 
Disintegration test 
The process of breakdown of a tablet into smaller particles is called as 
disintegration. The disintegration test was carried out on 6 tablets of 
each formulation by using USP disintegration apparatus in distilled 
water at 37±2 °C and the time in second is taken for complete 
disintegration of the tablet with no palatable mass remained in the 
apparatus was noted. Averages of six readings were taken [1]. 
Wetting time 
A piece of tissue paper folded twice was placed in a petri dish 
containing pH 6.8 phosphate buffer. A tablet was placed on paper 
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and time taken for complete wetting is noted. Averages of triplicate 
readings were taken [18]. 
Drug content uniformity 
Randomly ten tablets from each batch were weighed accurately 
and powdered; the equivalent weight of 100 mg of verapamil 
hydrochloride was taken and made the volume up to 100 ml with 
phosphate buffer pH 6.8 in 100 ml volumetric flask and kept aside 
with constant shaking for 24 h to extract the total drug present in 
the tablet. Then the solution was filtered, and the volume was 
made with phosphate buffer pH 6.8 and analyzed for drug content 
at λmax of 278 nm. Averages of triplicate were taken [19]. 
In vitro drug release 
Release of the drug in vitro, was determined by estimating the 
dissolution profile, USP 2 paddle apparatus was used and the paddle 
was allowed to rotate at 50 rpm, phosphate buffer (pH 6.8) (900 ml) 
was used as a dissolution medium. At specific time intervals of 0, 
1,3,9,12,15 min 5 ml of samples were withdrawn and measured the 
absorbance at 278 nm after suitable dilution with pH 6.8 phosphate 
buffer. Average of three readings was taken [20-23]. 
Stability study 
Stability study was conducted as per ICH guidelines 40°C±2°C, 
75%±2% RH to test the chemical and physical stability of fast 
dissolving tablets for the period of 2 mo [24].  
RESULTS AND DISCUSSION 
Determination of λ max of verapamil hydrochloride 
λ max of verapamil hydrochloride was determined in water. The 
calibration curve of verapamil hydrochloride shown linearity as per 
Beers Lambert’s law at 278 nm represented in fig. 1. 
  
 
Fig. 1: Calibration curve of verapamil hydrochloride in water 
 
 
Fig. 2: Drug+crosscarmellose sodium 
 
 
Fig. 3: Drug+sodium starch glycolate 
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Drug excipients compatibility study 
IR spectrometer study  
The IR spectra of verapamil hydrochloride, polymers, and physical 
mixture are shown in figures. The IR absorption bands observed in 
the IR spectrum of drug and polymers resembles with that of found 
in physical mixture proves compatibility of the drug with polymers. 
In fig. 2 absorption spectrum of drug and crosscarmellose sodium 
and in fig. 3 absorption spectrum of drug and sodium starch 
glycolate. 
Precompression evaluation parameters of powder 
Angle of repose 
The angle of repose is an inactive parameter of powder flow ability 
from the hopper to die cavity. An angle of repose between 25° to 30° 
indicates excellent flowability of the powder bed. In this work, the 
angle of repose was found to be varying between 22.56 °-31.68 ° when 
glidants were incorporated. These studies indicated that the powder 
beds of all formulations are easily flow able. All the precompressional 
parameters were found to be within the acceptable limit. 
Bulk density 
Bulk density was found in the range of 0.26±0.17 to 0.52±0.135 
g/ml.  
Tapped density 
Tapped density was found to be in the range of 0.28±0.1858 to 
0.59±0.207 g/ml.  
Percentage compressibility index 
Compressibility index was found to be in the range of 11.56 % 
to14.73 %. All formulations showed good flow properties which are 
given in table 3. 
 
Table 3: Precompression parameters for fast dissolving tablets of F1 to F9 
Formulation code *Angle of repose ( °)  *Bulk density (g/ml)  * Tapped density (g/ml)  Carr’s index (%) Hausner’s ratio 
F1 31.44±0.14 0.35±0.07 0.39±0.109 10.25 1.11 
F2 24.72±0.02 0.39±0.110 0.42±0.098 7.14 1.07 
F3 27.58±0.09 0.36±0.096 0.41±0.069 12.19 1.13 
F4 25.52±0.43 0.29±0.108 0.32±0.023 9.375 1.10 
F5 28.73±0.24 0.52±0.135 0.59±0.207 11.86 1.13 
F6 23.85±0.16 0.5±0.160 0.53±0.230 5.6 1.06 
F7 30.24±0.04 0.45±0.195 0.48±0.108 8.16 1.08 
F8 22.56±0.42 0.26±0.17 0.28±0.1858 7.14 1.07 
F9 31.68±0.05 0.33±0.145 0.37±0.138 10.81 1.12 
*All values are mean±SD of three determinations. SD: Standard deviation  
 
Post-compression evaluation of fast dissolving tablets of 
verapamil hydrochloride 
Hardness 
Hardness of the tablets varied between 2.8±0.11Kg/cm2to 3.1±0.25 
Kg/cm2
Drug content found in the fast dissolving tablets resembling that of 
literature value. Range of drug content is 90.8%-99.1%. Therefore 
uniformity of content was maintained in all formulations. Drug 
content of all formulations is listed in table 4. 
indicating good binding and satisfactory strength of tablets 
to withstand stresses during transportation and also may offer good 
dissolution property. 
% friability 
The % friability was found in the range of 0.50±0.12% to 
0.82±0.01%. The weight variation ranges from 149.7±0.44 to 
151±1.06 mg which passes the standard. 
Thickness 
The thickness of the tablets was found to be uniform, between 
2.68±0.19 mm to 2.84±0.02 mm for (F1 to F9). 
Drug content 
Weight variation 
The weight of the formulated tablets of verapamil hydrochloride (F1 
to F9) was found to be uniform with low standard deviation values 
from 149.2±1.25 to 151.3±0.69 mg. The prepared formulations 
comply with the weight variation test as per IP. The results are given 
in table 4. 
Wetting time 
It is the time required for complete wetting of tablet. The wetting 
time was found in the range of 16±0.55 to 25±0.57 sec.  
Disintegration time 
It is the time required for complete disintegration of the tablet. The 
disintegration time was found in the range of 19±0.06 to 27±0.57 sec. 
% cumulative drug release 
% cumulative drug release was found in the range of 87.12±0.599 to 
98.5±0.567 %. 
 






















F1 3.3±0. 20 2.84±0.02 0.67±0.02 150.9±0.17 25±0.57 27±0.57 90.8±0.92 
F2 3.2±0.05 2.8±0.04 0.50±0.12 151±1.06 20±0.23 23±0.53 93.2±0.81 
F3 2.9±0.05 2.83±0.08 0.63±0.05 150.1±0.63 22±0.57 26±1.15 95.8±0.50 
F4 3.1±0.23 2.82±0.15 0.72±1.35 149.2±1.25 18±1 20±0.28 94.7±0.62 
F5 2.9±0.11 2.70±0.07 0.59±0.13 151±0.86 20±0.17 23±0.79 97.2±0.88 
F6 3.2±0.15 2.68±0.19 0.82±0.01 149.7±0.44 24±0.28 27±0.55 98.5±0.71 
F7 3.1±0.25 2.74±0.21 0.68±0.16 151.3±0.69 18±0.32 21±0.27 97.7±0.87 
F8 2.8±0.11 2.77±0.06 0.59±0.10 150±0.73 16±0.55 19±0.06 99.1±0.94 
F9 3.3±0.45 2.80±0.26 0.67±0.17 150.1±0.68 19±0.29 23±0.36 98.9±0.79 
*All values are mean±SD of three determinations.  [SD: Standard deviation]  
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% cumulative drug release of the different formulations is shown 
in Fig.4. In this formulations as the level of croscarmellose 
sodium and sodium starch glycolate is increased the drug 
release will also increases. Release of the drug in vitro, was 
determined by estimating the dissolution profile, USP 2 paddle 
apparatus was used and the paddle was allowed to rotate at 50 




Fig. 4: Cumulative drug release of different formulation 
 
Table 5: Stability study of the optimized formulation 
S. No. Observations Before stability 
*(mean±SD) 
Stability testing interval days 
1 mo *(mean±SD) 2 mo *(mean±SD) 
1 Visual Appearance White  White  White  
2 disintegration time(sec)  19±0.06 19±0.30 21±0.11 
3 drug content 99.1±0.94 99.02±0.499 98.16±0.55 
*All values are mean±SD of three determinations. SD: Standard deviation  
 
Stability study 
Results of the stability studies showed that there is no change in the 
physical parameters of the formulation. Drug content of the 
formulation was also found to be same as that before stability 
testing. Stability data is shown in table 5. 
Optimization 
The purpose of 32
The influence of the main effect on responses was further ellucitated 
by response surface methodology. It is a widely used the tool in the 
development and design of the dosage form. The three-dimensional 
response surface plot and the corresponding two-dimensional 
countour plot were generated by software as shown in Fig. 5,6,7 and 
8. The response surface plot is very useful for the determination of 
the main and interaction effects of the independent variables 
whereas the two-dimensional plot gives a visual representation of 
values of responses.   factorial design was to conduct the 
comprehensive study of the effect of process parameters like 
croscarmellose sodium (X1) and sodium starch glycolate (X2) and 
their interactions using a suitable statistical tool (Design expert 
software version 9.0.2.0) by applying one way ANOVA at 0.05 levels. 
Mathematical modeling was carried out; the polynomial equation 
was obtained depending on significant influence among two factors 
on their experimental design.  
In case of in vitro drug release, the three-dimensional surface response 
plot depicted the increase in the drug release and disintegration time 
as increasing the concentration of superdisintegrants. The two-
dimensional countour plot relating X1X2 
  
(interaction between 
croscarmellose sodium and sodium starch glycolate) was nonlinear 
indicating interaction between two variables. 
 
Fig. 5: The counterplot showing the effect of croscarmellose sodium and sodium starch glycolate on disintegration time 
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Fig. 6: Surface response plot showing the effect of croscarmellose sodium and sodium starch glycolate on disintegration time 
 
 
Fig. 7: The counterplot showing the effect of croscarmellose sodium and sodium starch glycolate on % cumulative drug release 
 
 
Fig. 8: Surface response plot showing the effect of croscarmellose sodium and sodium starch glycolate on % cumulative drug release 
 
DISCUSSION 
Prepared formulations were subjected to various assessment 
parameters and the findings obtained were within the limits which 
are depicted in table 4. The hardness of all the tablets indicating 
good binding and satisfactory strength of tablets to withstand 
stresses during transportation and may offer good dissolution 
property. The thickness of the tablets was found to be uniform, and 
drug content of all formulations shows uniformity in the content of 
drug in each tablet. All the prepared formulations complies 
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disintegration and weight variation test as per IP. The F8 
formulation containing croscarmellose sodium and sodium starch 
glycolate in the ratio of (9:6) was selected as optimized formulation 
on the basis of the result of in vitro dissolution test. It is seen that in 
vitro drug release and disintegration increases as an enhancement of 
the concentration of superdisintegrants like croscarmellose sodium 
and sodium starch glycolate.  
CONCLUSION  
The current studies are aimed at successful development and 
optimization of the fast dissolving tablet of verapamil hydrochloride 
and to enhance the bioavailability of the drug by avoiding first pass 
effect. Among the prepared batches of tablets based on performance 
with respect to friability, hardness, uniformity of drug content, 
disintegration and in vitro drug release studies, F8 delivers the best 
results as compared to other formulations.  
Thus, drug release from the fast dissolving tablet was increased by 
using the increased concentration of superdisintegrants, assisting in 
faster disintegration in the oral cavity. As the drug having fast 
disintegration may leads to more drug availability for dissolution, 
resulting in faster absorption and possibly bioavailability leads to 
the quick onset of action in the systemic circulation.  
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